Groupe Athena, Inc. Reiterates Revenue Guidance Despite Currency Depreciation

MUMBAI, INDIA / ACCESSWIRE / May 24, 2016 / Groupe Athena, Inc. GATA announced today that the company is confident of meeting its projected revenue projections of $75 million in line with projections. The company also stated that it has an estimated $35 million of outstanding orders to provide a solid revenue base to build on for the 2017 fiscal period.

The company stated that since over 92% of its orders are dollar denominated, the significant rupee depreciation over the past year would have minimal effect on revenues this fiscal year.

The Indian pharmaceutical industry is estimated to be over $55 Billion in 2020 and is expected to experience 8% annual growth through the end of the decade. GATA has emerged as a vital component of this growth by its ability to help Indian manufacturers get their products approved by the FDA for sales in the US.

For more information on Groupe Athena, Inc. please go to www.otcmarkets.com/stock/GATA/quote or visit our corporate website at www.groupeathena.com.

About Groupe Athena, Inc.

Groupe Athena Inc. was incorporated in June 2008 and began operations on July 1 of that year. The company is a research and testing organization and helps various pharmaceutical and medical products and devices companies in India and Southeast Asia to get regulatory approvals and facilitate exports of their products to the United States. The Company accomplishes this by assisting clients from concept through development, providing consultation on regulatory requirements, filings and processes.

The company has a research and marketing facility in India that currently employs 22 consultants and marketing personnel and is working towards aggressively expanding its presence in the Indian pharmaceutical industry. The Company's web address is www.groupeathena.com

For more information contact:

Groupe Athena, Inc.
info@groupeathena.com
877-647-6876

Safe Harbor Statement

Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions -- activities of competitors and the presence of new or additional competition and conditions of equity markets.

SOURCE: Groupe Athena, Inc.